Abstract: The present disclosure provides compositions and methods for making and using engineered myeloid cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, wherein the chimeric receptor is encoded by a recombinant nucleic acid.

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Abstract: Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Abstract: A routing information transmission method includes before forwarding a service traffic packet, a first network device receives first Border Gateway Protocol (BGP) routing information from a second network device to determine a first forwarding table entry based on a service identifier and an identifier of a first network slice that are in the first BGP routing information. The first forwarding table entry indicates to forward, to the second network device using the first network slice, the service traffic. When receiving the service traffic packet corresponding to the service identifier, the first network device determines the first network slice based on the first forwarding table entry, and then sends the service traffic to the second network device using the first network slice.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: An aspect of the present invention is provided with a sensitive data protection code generating unit which generates a sensitive data protection code of a predetermined data length, a symmetric encryption key generating unit which generates a symmetric encryption key by using a key derivation function that takes, as input, the sensitive data protection code, a sensitive data encrypting unit which encrypts sensitive data by using the symmetric encryption key, a sensitive data protection code encrypting unit which encrypts the sensitive data protection code by using a public key provided from an sensitive data access support terminal, and a deleting unit which deletes the symmetric encryption key and the sensitive data after the encryption of the sensitive data, and deletes the sensitive data protection code after the encryption of the sensitive data protection code.

Abstract: The present disclosure provides compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.